TickerFacts.

Metagenomi Therapeutics, Inc. (MGX): Shareholders' Equity

Annual figures by period end, from SEC filings.

$158.60M
As of 2025-12-31
$112.57M
As of 2026-06-30
$234.86M2023-12-31: -$135.58M2024-12-31: $234.86M2025-12-31: $158.60M$158.60M
2023-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$158.60M-32.5%2026-03-05, Balance as of period end
2024-12-31$234.86Mn/m2026-03-05, Balance as of period end
2023-12-31-$135.58Mn/a2025-03-17, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Metagenomi Therapeutics, Inc. (MGX)2025-12-31$158.60M-32.5%
Alector, Inc. (ALEC)2025-12-31$30.65M-75.8%
Scilex Holding Co (SCLX)2025-12-31-$207.78Mn/m
LENZ Therapeutics, Inc. (LENZ)2025-12-31$284.34M+39.3%
Precision Biosciences Inc (DTIL)2025-12-31$92.25M+63.6%
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$186.29M+741.1%
C4 Therapeutics, Inc. (CCCC)2025-12-31$256.59M+18.8%
Pelthos Therapeutics Inc. (PTHS)2025-12-31$38.88Mn/m
Kymera Therapeutics, Inc. (KYMR)2025-12-31$1.58B+89.0%

Compare MGX, ALEC, SCLX, LENZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗